Introduction
In recent years, there has been a growing interest in the influence of skeletal muscle (radio-) density on cancer prognosis. Skeletal muscle density, measured by computed tomography (CT) and quantified in Hounsfield units (HU), reflects the lipid content of the muscle cells (Goodpaster et al. 2000); higher muscle lipid content in the muscle cells presents as lower skeletal muscle density (Goodpaster et al. 2000). Lower skeletal muscle density has been found to be associated with higher total adiposity (Goodpaster et al. 2001), obesity (Lee et al. 2005) and increasing age (Anderson et al. 2013). In a recent study, an association between low skeletal muscle density and pre-existing comorbidities was also reported suggesting a potential shared mechanism between fat infiltration in the muscle and comorbidities (Xiao et al. 2018).
Various studies have reported an association between low skeletal muscle density and higher mortality (Sjøblom et al. 2016; Fujiwara et al. 2015; Rier et al. 2017; Dijk et al. 2017; Blauwhoff-Buskermolen et al. 2016b; Ebadi et al. 2017; Antoun et al. 2013) in cancer patients. Until now, majority of the studies have been performed in late-stage (stage IV) cancer patients (Sjøblom et al. 2016; Rier et al. 2017; Blauwhoff-Buskermolen et al. 2016b) and/or in cancer types with poor prognosis (Fujiwara et al. 2015; Dijk et al. 2017; Ebadi et al. 2017). Three studies (van Vugt et al. 2018; McSorley et al. 2017; Kroenke et al. 2018) investigated the association between skeletal muscle density and mortality exclusively in early-stage (stage I–III) colorectal (CRC) patients, who have a much better prognosis than stage V patients [i.e., 5 year survival rate of > 70 vs < 15% in late-stage CRC (Siegel et al. 2017)], and results were not consistent. The first two studies were performed in European populations and did not show significant associations between skeletal muscle density and overall mortality (van Vugt et al. 2018; McSorley et al. 2017), CRC-specific mortality (McSorley et al. 2017) or disease-free survival (van Vugt et al. 2018) in early-stage CRC patients after adjusting for confounding factors. A caveat is that both studies used cut-off points for low muscle density, which were defined in a mixed group of cancer patients of various diagnosis, mostly with very poor prognosis (Martin et al. 2013). Those cut-off points may not be appropriate in an early-stage European CRC patient population. The third study, performed in the US (Kroenke et al. 2018) reported that lower skeletal muscle density was associated with higher overall and CRC-specific mortality. Given the inconsistency of findings so far and the challenges in the interpretation in a European population, we decided to study the association between skeletal muscle density and overall mortality in a large cohort of European early-stage CRC patients. Furthermore, we investigated the association between skeletal muscle density and CRC-specific mortality and disease-free survival in a subset of the study population.
Anzeige
Materials and methods
Subjects
Data from two ongoing prospective cohort studies (n = 1111) were combined with registry-based data from three hospitals (n = 1537). The prospective cohort studies, i.e., the COLON (Winkels et al. 2014) and EnCoRe (van Roekel et al. 2014) studies, started in 2010 and 2012, respectively. Both investigated the role of lifestyle in CRC patients; details have been described earlier (Winkels et al. 2014; van Roekel et al. 2014). CRC patients included in the COLON study participants were diagnosed between August 2010 and November 2015; CRC patients included in the EnCoRe study were diagnosed between April 2012 and November 2014. For the registry-based data, the Netherlands Cancer Registry was used to select all stage I–III CRC patients diagnosed between January 2007 and December 2010 in two hospitals and January 2007 and January 2013 in a third hospital.
For all cohorts, exclusion criteria were: missing data on height, weight, stage of disease or comorbidities; stage IV CRC; missing or unusable CT images (i.e., CT images of poor quality or scans where muscle tissue was partly cut-off). Furthermore, only pre-operative CT images assessed within 3 months of diagnosis were considered representative for skeletal muscle status at diagnosis.
The COLON study was approved by the Committee on Research involving Human Subjects, region Arnhem–Nijmegen, the Netherlands. The EnCoRe study was approved by the Medical Ethics Committee of the University Hospital Maastricht and Maastricht University, the Netherlands. All participants of the COLON and EnCoRe study provided written informed consent. According to the Central Committee on Research involving Human Subjects (CCMO), studies using the data of the Netherlands Cancer Registry do not require approval from an ethics committee in the Netherlands. The study was approved by the Privacy Review Board of the Netherlands Cancer Registry. In addition, the ethical committees of the three participating hospitals gave permission to use additional data from CT images.
Body composition and anthropometry
Skeletal muscle cross-sectional area was assessed using pre-operative CT images at the level of the 3rd lumbar vertebrae. Skeletal muscle was quantified using Slice-O-Matic 5.0 (Tomovision, Montreal, Canada). Standard density thresholds were used to define skeletal muscle: − 29 to + 150 HU (Mitsiopoulos et al. 1998). Standardized procedures were followed by trained researchers to correctly identify and quantify the psoas, erector spinae, quadratus lumborum, transversus abdominis, external and internal obliques, and rectus abdominis. Skeletal muscle density was measured as the mean density (in HU) of the total skeletal muscle cross-sectional area. Furthermore, as potential confounders, visceral adipose tissue, subcutaneous adipose tissue and intermuscular adipose tissue were quantified using the following standard density thresholds: − 150 and − 50 HU for visceral adipose tissue; − 190 and − 30 HU for both subcutaneous and intermuscular adipose tissue. Total adipose tissue was calculated as the sum of visceral, subcutaneous and intermuscular adipose tissue.
Anzeige
The association between skeletal muscle density and overall mortality, CRC-specific mortality and disease-free survival were assessed using continuous and dichotomized (low vs normal skeletal muscle density) variables. For the identification of patients with low skeletal muscle density, gender- and body mass index (BMI)-specific cut-off values were determined using optimal stratification (Williams 2006), which is a statistical method previously used in comparable studies (Martin et al. 2013; Prado et al. 2008; Caan et al. 2017) using a macro in SAS (version 9.3; SAS Institute, Cary, NC, USA). We decided to create specific cut-off values for our population, as established cut-off values to identify and low skeletal muscle density had been determined within cancer populations with a much higher mortality rate (Martin et al. 2013) or in other continents (North America) (Kroenke et al. 2018) which might not be representative for a European cohort. As acknowledged by others (Blauwhoff-Buskermolen et al. 2016a; Daly et al. 2016), reference cut-off values for an European population are important because of possible differences in body composition and prevalence of obesity between European, US and other populations. This optimal stratification procedure, resulted in the following cut-off levels for skeletal muscle density: for men with a BMI < 25 kg/m2 the cut-off value for low skeletal muscle density was 36.4 HU, for men with a BMI ≥ 25 kg/m2 31.6 HU; for women with a BMI < 25 kg/m2 31.1 HU; for women with a BMI ≥ 25 kg/m2 29.3 HU.
Height (m) and weight (kg) at diagnosis were self-reported within the COLON study; measured by trained research assistants within the EnCoRe study; and collected from medical records by the Netherlands Cancer Registry for the registry-based data.
Medical history and mortality
Data on age, gender, type of cancer, stage of disease, comorbidities, and date of surgery were collected from medical records for the prospective cohort studies and from the Netherlands Cancer Registry for the registry-based data. Mortality data were retrieved from the Municipal Personal Records Database. Overall mortality was measured as number of months alive after the assessment date of the CT image until time of death or January 31, 2017. Patients who were alive on this date were censored. For participants of the COLON study (n = 715), recurrence data was retrieved in collaboration with the Netherlands Cancer Registry and cause of death was obtained by linkage with Statistics Netherlands (CBS). The International Classification of Diseases 10th Revision (ICD-10) was used to identify CRC-specific mortality (ICD-10 codes C18–C20). DFS was calculated as number of months between the assessment date of the CT image and either a recurrence, metastasis of disease, or death from any cause.
Statistical analyses
Hazard ratios (HR) and corresponding 95% confidence intervals (CI) for overall mortality, CRC-specific mortality and disease-free survival were obtained using Cox proportional hazard analyses. Proportional hazard assumptions were tested by log–log curves, with no violations noted.
The model for overall mortality was tested for effect modification by gender, age and number of comorbidities (0, 1, ≥ 2), by calculating the p value for interaction. Of these variables, the number of comorbidities was the only variable that was identified as an effect modifier for skeletal muscle density. Thus, the models for skeletal muscle density and overall mortality were stratified for number of comorbidities. Since no difference was found between zero and one comorbidity, these two categories were combined into one category: the final model was stratified into two groups (i.e., 0–1 comorbidity vs ≥ 2 comorbidities). Data on cause of death, recurrence and metastasis, were only available for the COLON study. Due to the limited sample size of the COLON study population (n = 715), statistical power precluded the possibility to assess effect modification in the analyses for CRC-specific mortality and disease-free survival.
Based on existing literature, age, stage of disease and gender were selected as potential confounding variables and were included in the final multivariable Cox proportional hazard models. Other variables, i.e., BMI (continuous and categorical), study type (prospective or registry-based), tumor location (colon or rectal), treatment (chemotherapy yes or no; radiotherapy yes or no), number of comorbidities (0–1 or ≥ 2), skeletal muscle index (i.e., skeletal muscle mass corrected for height in meters squared), visceral adipose tissue, subcutaneous adipose tissue and total adipose tissue were included in the final model if they changed the HR for mortality with 10% or more when the variable was individually added to the model. Based on these criteria, only age, gender and stage were included in the final adjusted models.
As a sensitivity analyses, we repeated all analyses, excluding patients who died or had a recurrence or death within 1 year of follow-up.
Level of significance was set at 0.05. Analyses were performed using IBM SPSS 23.0 (SPSS Inc., Chicago, IL, USA).
Anzeige
Results
Out of 2648 eligible patients, data from 580 patients had to be excluded because either no CT images were available, no pre-surgical CT image within 3 months of diagnosis was available, or the CT image was unusable due to low quality. An additional 68 patients were excluded because the stage of disease was unknown, for 282 patients data on height and/or weight were missing and for 37 patients comorbidity data were missing (Fig. 1). The final dataset consisted of 1681 patients. The average age of the 967 excluded patients was 68.5 ± 12.4 years; 43% were women; 61% had a tumor located in the colon; and of the excluded patients with stage of disease data available (79%), 26% had stage I disease, 38% stage II and 36% stage III CRC.
Fig. 1
Flowchart of the study
×
![]()
The average age of the study population was 67.7 ± 10.3 years and 41% were women; 67% of the patients had a tumor located in the colon (Table 1). The majority of these patients had a BMI between 25 and 29.9 kg/m2 (43%) or 20–24.9 kg/m2 (36%), while 17% had a BMI ≥ 30 kg/m2 and 4% a BMI < 20 kg/m2. In total, 414 patients (25%) died before January 31, 2017 and the median follow-up time was 48 months (range 0–119 months).
Table 1
Baseline characteristics in early-stage CRC patients with or without low skeletal muscle density
Total population (n = 1681) | Skeletal muscle density | ||
|---|---|---|---|
Low (n = 648) (39%) | Normal (n = 1033) (61%) | ||
Demographic factors | |||
Age [years, mean (SD)] | 67.7 (10.3) | 73.2 (8.8) | 64.3 (9.7) |
Gender [n (%)] | |||
Men | 999 (59) | 372 (57) | 627 (61) |
Women | 682 (41) | 276 (43) | 406 (39) |
BMI [kg/m2, mean (SD)] | |||
BMI [kg/m2, n (%)] | |||
< 20 | 65 (4) | 17 (3) | 48 (5) |
20–24.9 | 609 (36) | 238 (37) | 371 (36) |
25–29.9 | 718 (43) | 238 (37) | 480 (47) |
≥ 30 | 289 (17) | 155 (24) | 134 (13) |
Clinical factors | |||
Cancer stage [n (%)] | |||
I | 393 (23) | 127 (20) | 266 (26) |
II | 547 (33) | 251 (39) | 296 (29) |
III | 741 (44) | 270 (42) | 471 (46) |
Tumor location [n (%)]a | |||
Colon | 1123 (67) | 465 (72) | 658 (64) |
Rectal | 552 (33) | 180 (28) | 372 (36) |
Number of comorbidities [n (%)] | |||
0–1 | 966 (58) | 283 (44) | 683 (66) |
≥ 2 | 715 (43) | 365 (56) | 350 (34) |
Treatment | |||
Radiotherapy [n (%)]b | |||
No | 1136 (73) | 462 (77) | 674 (71) |
Yes | 419 (27) | 140 (23) | 279 (29) |
Chemotherapy [n (%)]c | |||
No | 1117 (72) | 471 (78) | 646 (68) |
Yes | 440 (28) | 130 (22) | 310 (32) |
CT image analysis | |||
Skeletal muscle index [cm2/m2, mean (SD)] | |||
Men | 51 (8) | 48 (8) | 53 (7) |
Women | 40 (6) | 39 (6) | 41 (6) |
Muscle attenuation [HU, mean (SD)] | |||
Men | 36 (8) | 27 (5) | 41 (5) |
Women | 32 (10) | 23 (5) | 39 (7) |
Visceral adipose tissue [cm2, median (range)] | 147 (0–535) | 168 (1–535) | 133 (0–495) |
Subcutaneous adipose tissue [cm2, median (range)] | 159 (0–713) | 166 (0–713) | 154 (1–596) |
Total adipose tissue [cm2, median (range)] | 341 (5–1070) | 383 (35–1070) | 316 (5–924) |
Study [n (%)] | |||
Prospective | 852 (51) | 242 (37) | 610 (59) |
Registry-based | 829 (49) | 406 (63) | 423 (41) |
Follow-up time [months, median (range)] | 48 (0–119) | 48 (0–119) | 48 (0–119) |
Deceased patients [n (%)] | 414 (25) | 261 (40) | 153 (15) |
Anzeige
Thirty-nine percent of the patients had low skeletal muscle density (Table 1). Mean age and the percentage of women were higher in the low skeletal density group compared to the normal skeletal density group (73.2 ± 8.8 vs 64.3 ± 9.7 years; 43 vs 39%, respectively). Furthermore, the percentage of patients with a BMI ≥ 30 kg/m2 was higher in the low skeletal density group compared to the normal skeletal density group (24 vs 13%, respectively), while the percentage of patients with a BMI 25–29.9 kg/m2 was lower in the low skeletal muscle density group vs. the normal skeletal density group (37 vs 47%).
Data for CRC-specific mortality and disease-free survival were only available for participants of the COLON study. The average age of these patients was slightly lower than in the total study population: 65.6 ± 9.1 vs 67.7 ± 10.3 years (Table 2). Furthermore, the follow-up time was shorter (i.e., 37 vs. 48 months) and the percentage of deceased patients was lower (i.e., 11 vs. 25%). Other variables were comparable with the total population. Twenty-seven percent of the patients had low skeletal muscle density.
Table 2
Baseline characteristics of the participants from the COLON study
COLON study (n = 715) | Skeletal muscle density | ||
|---|---|---|---|
Low (n = 196) (27%) | Normal (n = 519) (73%) | ||
Demographic factors | |||
Age [years, mean (SD)] | 65.6 (9.1) | 70.8 (7.8) | 63.8 (8.9) |
Gender [n (%)] | |||
Men | 440 (62) | 122 (62) | 318 (61) |
Women | 275 (39) | 71 (38) | 201 (39) |
BMI [kg/m2, n (%)] | |||
< 20 | 25 (4) | 6 (3) | 19 (4) |
20–24.9 | 255 (36) | 75 (38) | 180 (35) |
25–29.9 | 316 (44) | 64 (33) | 252 (49) |
≥ 30 | 119 (17) | 51 (26) | 68 (13) |
Clinical factors | |||
Cancer stage [n (%)] | |||
I | 210 (29) | 56 (29) | 154 (30) |
II | 204 (29) | 63 (32) | 141 (27) |
III | 301 (42) | 77 (39) | 224 (43) |
Tumor location [n (%)] | |||
Colon | 483 (68) | 136 (69) | 247 (67) |
Rectal | 232 (32) | 60 (31) | 172 (33) |
Number of comorbidities [n (%)] | |||
0–1 | 444 (62) | 103 (53) | 341 (66) |
≥ 2 | 271 (38) | 93 (47) | 178 (34) |
Follow-up time [months, median (range)] | 37 (1–77) | 38 (3–77) | 36 (1–77) |
Deceased patients [n (%)] | 76 (11) | 40 (24) | 36 (7) |
Low skeletal muscle density was significantly associated with higher mortality (low vs. normal skeletal muscle density: adjusted HR 1.91, 95% CI 1.53–2.38), Table 3. Number of comorbidities was identified as an effect modifier (p value for interaction = 0.02). In the stratified analysis, low skeletal muscle density was significantly associated with higher mortality in patients with zero or one comorbidities (low vs. normal skeletal muscle density: adjusted HR 1.67, 95% CI 1.20–2.31), yet this association was even stronger in the group of patients with two or more comorbidities (low vs. normal skeletal muscle density: adjusted HR 2.11, 95% CI 1.55–2.87).
Anzeige
Table 3
Association between skeletal muscle density and overall mortality
No. of patients | No. of deaths n (%) | HR (95% CI)a | |
|---|---|---|---|
Skeletal muscle density, total population | |||
Normal | 1033 | 153 (15) | REF |
Low | 648 | 261 (40) | 1.91 (1.53–2.38) |
Skeletal muscle density, 0–1 comorbidities | |||
Normal | 683 | 93 (14) | REF |
Low | 283 | 88 (31) | 1.67 (1.20–2.31) |
Skeletal muscle density, ≥ 2 comorbidities | |||
Normal | 350 | 60 (17) | REF |
Low | 365 | 173 (47) | 2.11 (1.55–2.87) |
Skeletal muscle density, HU (continuous) | 1681 | 414 (25) | 0.98 (0.96–0.99) |
Within the sub-population of the COLON study (n = 715), low skeletal muscle density was associated with higher overall mortality (low vs. normal skeletal muscle density: adjusted HR 2.15, 95% CI 1.32–3.50) and worse disease-free survival (low vs. normal skeletal muscle density: adjusted HR 1.68, 95% CI 1.14–2.47), but not significantly with colorectal cancer-specific disease (low vs. normal: adjusted HR 1.68, 95% CI 0.89–3.17) (Table 4).
Table 4
Association between skeletal muscle density and overall mortality, CRC-specific mortality and disease-free survival in a sub-population (n = 715)
No. of patients | No. of deaths n (%) | HR (95% CI)a | |
|---|---|---|---|
Overall mortality | |||
Skeletal muscle density | |||
Normal | 519 | 36 (7) | REF |
Low | 196 | 40 (20) | 2.15 (1.32–3.50) |
CRC-specific mortality | |||
Skeletal muscle density | |||
Normal | 519 | 26 (5) | REF |
Low | 196 | 19 (10) | 1.68 (0.89–3.17) |
Disease-free survival | |||
Skeletal muscle density | |||
Normal | 519 | 72 (14) | REF |
Low | 196 | 52 (27) | 1.68 (1.14–2.47) |
Discussion
In our cohort of early-stage CRC patients, low skeletal muscle density was significantly associated with higher mortality. This association was strongest in patients with ≥ 2 comorbidities. Within a subset of the total study population, data on disease-free survival and cause of death were available, and low skeletal muscle density was associated with worse disease-free survival, but not statistically significantly with CRC-specific survival.
Our findings support the findings from Kroenke et al. (2018), who also found that low skeletal muscle density was associated with worse survival. Although speculative, our findings also underline the importance of using cut-off points for low skeletal muscle density that are defined in an appropriate population, as two other studies did not find associations between muscle density and survival (van Vugt et al. 2018; McSorley et al. 2017). The cut-off points we defined in our study population, are very comparable to the cut-offs defined in the study by Kroenke et al. (2018). The two studies that did not find associations, used cut-off levels for low skeletal muscle density that were defined in mixed group of cancer patients of various diagnoses, mostly with very poor prognosis (Martin et al. 2013).
In the present study, we did not find a statistically significant association between low skeletal muscle density and CRC-specific mortality. This might just be a matter of limited statistical power, as data on CRC-specific mortality were only available for the sub-population of participants enrolled in the COLON study. In the large study by Kroenke et al. (2018), an association was found with higher CRC-specific mortality. Further studies are needed to understand the mechanisms behind the association of skeletal muscle density and survival.
In the present study, the associations between low muscle density and both higher overall mortality and lower disease-free survival were independent of age, adipose tissue and BMI, suggesting that the patients with higher risk of dying were not just the older, obese CRC patients. It could be possible that patients with a high skeletal muscle density were more physically active in daily life. Studies investigating the effect of training and detraining (i.e., the effect of reduced physical training after a training program), and of strength and endurance training showed that those training programs increased skeletal muscle density (Lee et al. 2005; Taaffe et al. 2009; Poehlman et al. 2000), whereas detraining reduced skeletal muscle density (Taaffe et al. 2009). Very limited data are available on other determinants of skeletal muscle density, thus, whether other lifestyle factors like smoking and drinking are associated with decreased skeletal muscle density is still unknown.
We showed that the association of low muscle density and higher mortality was strongest among patients with multiple comorbidities. In a recent study (Xiao et al. 2018), an association between low skeletal muscle density and comorbidities was reported. Yet, our results suggests that lower skeletal muscle density is not simply a measure of worse health status, as among those patients with more comorbidities (thus with worst health status), the association was strongest. Potentially, the health status of those patients makes them extra vulnerable for the detrimental effects of fat infiltration in the muscle, but mechanistic studies are needed to explore this further.
This study has some limitations. First, data from patients without a CT image within 3 months of diagnosis had to be excluded. Since CT-diagnostic imaging was not common practice in clinical care of CRC in the Netherlands until 2008, a lot of scans were missing for patients diagnosed before 2008. Mean age, percentage of women, stage of disease and percentage of colon tumors were comparable between the included and excluded patient group. Therefore, we do not expect that excluding these patients affected our results. Second, due to the availability of cause of death and recurrence data, we could only perform the analyses for CRC-specific mortality and disease-free survival in the participants of the COLON study (n = 715).
This is the first large-scale European cohort that assessed the association between skeletal muscle density and survival with cut-off points relevant for/defined in our cohort of early-stage CRC patients. Other strengths are the large sample size, the long follow-up time and the inclusion of exclusively early-stage CRC patients.
In conclusion, low skeletal muscle density was significantly associated with higher overall mortality and lower disease-free survival in early-stage CRC patients. Future observational studies are needed to study which factors determine low skeletal muscle density. Thereafter, intervention studies should be performed to study whether intervening action taken on skeletal muscle density could improve prognosis of cancer patients, e.g., with nutritional interventions and/or exercise training.
Acknowledgements
The authors would like to thank all patients and participating hospitals. Furthermore, the authors would like to thank L. Posthuma, P. Goldsteen, M. Verhoeven, A. Pakkert, C. Aller, A. Adriaans, I. Akkerman for all their help during this study.
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.